June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
LUMINOUS: baseline characteristics of the first cohort of patients treated with ranibizumab 0.5 mg in routine clinical practice
Author Affiliations & Notes
  • Christopher Brand
    Royal Hallamshire Hospital, Sheffield, United Kingdom
  • Footnotes
    Commercial Relationships Christopher Brand, Allergan (C), Allergan (F), Allergan (R), Bayer (C), Merck (R), Pfizer (F), Quark Pharmaceuticals (F), Novartis (C), Novartis (F), Novartis (R), Sharp (R), Dohme (MSD) (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3831. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christopher Brand, ; LUMINOUS: baseline characteristics of the first cohort of patients treated with ranibizumab 0.5 mg in routine clinical practice. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3831.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

LUMINOUS is a 5-year, global, prospective, observational, long-term study being conducted to evaluate the safety and effectiveness of ranibizumab 0.5 mg in patients with age-related macular degeneration (AMD), diabetic macular edema (DME) and retinal vein oclusion (RVO) in routine clinical practice, treated in accordance with the local product label

 
Methods
 

The study aims to enrol 30,000 patients from approximately 500 centres in 34 countries worldwide. Here we report the baseline characteristics of the first cohort of patients enrolled from March 2011 to February 2012

 
Results
 

A total of 1915 patients in this recruitment period were included in the analysis. Since majority of the patients (n=1877) have neovascular (n) AMD, here we report the baseline characteristics of nAMD patients. The mean age of these patients is 79.2 years, 61.7% are female, and 93.0% are Caucasian. Demographic characteristics such as age, gender and race are well-balanced between treatment-naïve (T1) and treatment non-naive (T2) groups. Fifty-eight percent of patients are treatment non-naive; median time since nAMD diagnosis to baseline is 0.9 years for T1 patients and 1.9 years for T2 patients. At baseline, mean visual acuity was 55.8 (T1) and 57.7 (T2) letters and central retinal thickness was 283.0 (T1) and 251.0 (T2) µm. Overall, 31.0% of patients had predominantly classic type of lesion, 42.0% had pigment epithelium detachment, 2.2% had polypoidal choroidal vasculopathy and 3.1% had retinal angiomatomous proliferation at baseline

 
Conclusions
 

LUMINOUS trial is successfully enrolling patients (more than 7726 patients recruited by Dec, 2012), and the overall baseline characteristics are as expected in a real-world setting

 
 
Other baseline characteristics of nAMD patients by prior treatment group
 
Other baseline characteristics of nAMD patients by prior treatment group
 
Keywords: 412 age-related macular degeneration • 754 visual acuity  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×